Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Petry, Karl-Ulrich, Bollaerts, Kaatje, Bonanni, Paolo, Stanley, Margaret, Drury, Rosybel, Joura, Elmar, Kjaer, Susanne K., Meijer, Chris J. L. M., Riethmuller, Didier, Soubeyrand, Benoit, Van Damme, Pierre, Bosch, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067852/
https://www.ncbi.nlm.nih.gov/pubmed/29553886
http://dx.doi.org/10.1080/21645515.2018.1450125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067852/
https://www.ncbi.nlm.nih.gov/pubmed/29553886
http://dx.doi.org/10.1080/21645515.2018.1450125

Ejemplares similares